Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock.
This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that it has entered into a definitive agreement to acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.
Apogee's pipeline includes zumilokibart (APG777), a lead **** et. It is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being developed as a treatment for atopic dermatitis. The company is also developing APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, for the treatment of asthma.
H.C. Wainwright noted that both Apogee and Oruka Therapeutics, Inc. (NASDAQ:ORKA) were created by privately-held Paragon Therapeutics and share several similarities. The firm said both companies focus on developing treatments for inflammatory and immune-related diseases, with a particular emphasis on inflammatory skin conditions.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biopharmaceutical company focused on developing novel biologics for the treatment of chronic skin diseases.
This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that it has entered into a definitive agreement to acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.
Apogee's pipeline includes zumilokibart (APG777), a lead **** et. It is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being developed as a treatment for atopic dermatitis. The company is also developing APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, for the treatment of asthma.
H.C. Wainwright noted that both Apogee and Oruka Therapeutics, Inc. (NASDAQ:ORKA) were created by privately-held Paragon Therapeutics and share several similarities. The firm said both companies focus on developing treatments for inflammatory and immune-related diseases, with a particular emphasis on inflammatory skin conditions.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biopharmaceutical company focused on developing novel biologics for the treatment of chronic skin diseases.
4 months ago
